Tuberc Respir Dis.  2011 Dec;71(6):417-424.

Association of p53 Expression with Metabolic Features of Stage I Non-Small Cell Lung Cancer

• Kang SM
• Koh WJ
• Suh GY
• Chung MP
• Han J
• Kim H
• Kwon OJ
• Um SW

Abstract

BACKGROUND
Recent evidences have revealed metabolic functions of p53 in cancer cells; adaptation or survival to metabolic stress and metabolic shift toward oxidative phosphorylation. However, further studies in clinical setting are needed. We investigated whether p53 protein expression, as a surrogate marker for loss of p53 function, is associated with metabolic features of stage I non-small cell lung cancer (NSCLC), focusing on tumor necrosis and maximal standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography.
METHODS
Clinical information was obtained from retrospective review of medical records. p53 expression was assessed by immunohistochemical staining.
RESULTS
p53 protein expression was detected in 112 (46%) of 241 NSCLC cases included in this study. p53 expression was independently associated with the presence of necrosis (odds ratio [OR], 2.316; 95% confidence interval [CI], 1.215~4.416; p=0.011). Non-adenocarcinoma histology (OR, 8.049; 95% CI, 4.072~15.911; p<0.001) and poorly differentiation (OR, 6.474; 95% CI, 2.998~13.979; p<0.001) were also independently associated with the presence of necrosis. However, p53 expression was not a significant factor for SUVmax.
CONCLUSION
p53 protein expression is independently associated with the presence of necrosis, but not SUVmax.

Keyword

Tumor Suppressor Protein p53; Necrosis; Positron-Emission Tomography; Carcinoma, Non-Small-Cell Lung

MeSH Terms

Biomarkers
Carcinoma, Non-Small-Cell Lung
Electrons
Medical Records
Necrosis
Oxidative Phosphorylation
Positron-Emission Tomography
Retrospective Studies
Stress, Physiological
Tumor Suppressor Protein p53
Tumor Suppressor Protein p53

Figure

• 

  Figure 1 Surgical specimens of non-small cell lung cancer without necrosis (A) or with necrosis (B, arrow) (H&E stain, ×100). Immunostainings for p53 (C~F). No p53 expression was observed in the nuclei of non-small cell lung cancer without necrosis (C, p53 immunostaining, ×100; E, p53 immunostaining, ×400). p53 is strongly expressed in the nuclei of non-small cell lung cancer with necrosis (D, p53 immunostaining, ×100; F, p53 immunostaining, ×400).

Reference

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997. 88:323–331.

2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000. 408:307–310.

3. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006. 126:107–120.

4. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005. 65:177–185.

5. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science. 2006. 312:1650–1653.

6. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007. 67:6745–6752.

7. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005. 18:283–293.

8. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, et al. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem. 2008. 283:3979–3987.

9. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989. 246:491–494.

10. Ahrendt SA, Chow JT, Yang SC, Wu L, Zhang MJ, Jen J, et al. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res. 2000. 60:3155–3159.

11. Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev. 2008. 27:545–554.

12. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry?--Revisited! J Pathol. 1994. 172:1–4.

13. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer. 2004. 45:19–27.

14. Kwon YM, Park JH, Kim H, Shim YM, Kim J, Han J, et al. Different susceptibility of increased DNMT1 expression by exposure to tobacco smoke according to histology in primary non-small cell lung cancer. J Cancer Res Clin Oncol. 2007. 133:219–226.

15. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol. 2008. 3:6–12.

16. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, et al. Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009. 137:43–48.

17. Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007. 34:1610–1616.

18. van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007. 43:1392–1398.

19. Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun. 2004. 25:11–17.

20. Zhang ZJ, Chen JH, Meng L, Du JJ, Zhang L, Liu Y, et al. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer. Chin Med J (Engl). 2007. 120:125–131.

21. Bacharach SL, Sundaram SK. 18F-FDG in cardiology and oncology: the bitter with the sweet. J Nucl Med. 2002. 43:1542–1544.

22. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat. 2003. 21:229–239.

23. D'Amico TA, Massey M, Herndon JE 2nd, Moore MB, Harpole DH Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg. 1999. 117:736–743.

24. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res. 2000. 6:4055–4063.

25. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001. 18:705–719.

26. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986. 46:8 Suppl. 4244s–4248s.